ST Pharm Co.,Ltd. (237690.KQ)

KRW 79400.0

(0.51%)

Operating Expenses Summary of ST Pharm Co.,Ltd.

ST Pharm Co.,Ltd.'s latest annual operating expenses in 2023 was 75.59 Billion KRW , up 15.54% from previous year.
ST Pharm Co.,Ltd.'s latest quarterly operating expenses in 2024 Q2 was 47.65 Billion KRW , up 200.46% from previous quarter.
ST Pharm Co.,Ltd. reported a annual operating expenses of 65.42 Billion KRW in annual operating expenses 2022, up 35.36% from previous year.
ST Pharm Co.,Ltd. reported a annual operating expenses of 48.33 Billion KRW in annual operating expenses 2021, up 36.63% from previous year.
ST Pharm Co.,Ltd. reported a quarterly operating expenses of 47.65 Billion KRW for 2024 Q2, up 200.46% from previous quarter.
ST Pharm Co.,Ltd. reported a quarterly operating expenses of 57.1 Billion KRW for 2024 Q3, down -65.63% from previous quarter.

Annual Operating Expenses Chart of ST Pharm Co.,Ltd. (2023 - 2015)

Historical Annual Operating Expenses of ST Pharm Co.,Ltd. (2023 - 2015)

Year	Operating Expenses	Operating Expenses Growth
2023	75.59 Billion KRW	15.54%
2022	65.42 Billion KRW	35.36%
2021	48.33 Billion KRW	36.63%
2020	35.37 Billion KRW	47.98%
2019	23.9 Billion KRW	35.02%
2018	17.7 Billion KRW	2.3%
2017	17.3 Billion KRW	12.83%
2016	15.34 Billion KRW	35.63%
2015	11.31 Billion KRW	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	15.85 Billion KRW	-11.32%
2024 Q2	47.65 Billion KRW	200.46%
2024 Q3	57.1 Billion KRW	-65.63%
2023 Q2	19.28 Billion KRW	-5.9%
2023 Q3	15.88 Billion KRW	-17.63%
2023 Q4	17.88 Billion KRW	12.58%
2023 FY	75.59 Billion KRW	15.54%
2023 Q1	20.49 Billion KRW	5.61%
2022 Q1	14.95 Billion KRW	5.96%
2022 Q4	19.4 Billion KRW	24.78%
2022 FY	65.42 Billion KRW	35.36%
2022 Q3	15.55 Billion KRW	0.18%
2022 Q2	15.52 Billion KRW	3.83%
2021 Q4	14.11 Billion KRW	8.88%
2021 FY	48.33 Billion KRW	36.63%
2021 Q3	12.95 Billion KRW	14.7%
2021 Q2	11.29 Billion KRW	9.04%
2021 Q1	10.36 Billion KRW	-38.47%
2020 Q2	1.02 Billion KRW	-86.19%
2020 Q3	9.83 Billion KRW	857.35%
2020 Q4	16.84 Billion KRW	71.2%
2020 FY	35.37 Billion KRW	47.98%
2020 Q1	7.44 Billion KRW	-47.53%
2019 Q4	14.18 Billion KRW	414.43%
2019 Q2	3.95 Billion KRW	17.08%
2019 Q1	3.37 Billion KRW	-54.37%
2019 FY	23.9 Billion KRW	35.02%
2019 Q3	2.75 Billion KRW	-30.25%
2018 Q1	3.65 Billion KRW	-62.86%
2018 Q3	4.13 Billion KRW	82.17%
2018 FY	17.7 Billion KRW	2.3%
2018 Q2	2.26 Billion KRW	-37.97%
2018 Q4	7.4 Billion KRW	79.05%
2017 Q4	9.84 Billion KRW	124.7%
2017 Q3	4.38 Billion KRW	82.99%
2017 FY	17.3 Billion KRW	12.83%
2017 Q2	2.39 Billion KRW	-51.6%
2017 Q1	4.94 Billion KRW	21.4%
2016 Q4	4.07 Billion KRW	10.55%
2016 Q2	4.03 Billion KRW	4142.81%
2016 FY	15.34 Billion KRW	35.63%
2016 Q1	95.01 Million KRW	-91.7%
2016 Q3	3.68 Billion KRW	-8.54%
2015 Q3	3.87 Billion KRW	-19.61%
2015 Q4	1.14 Billion KRW	-70.44%
2015 Q2	4.81 Billion KRW	0.0%
2015 FY	11.31 Billion KRW	0.0%

Peer Operating Expenses Comparison of ST Pharm Co.,Ltd.

Name	Operating Expenses	Operating Expenses Difference
Sam Chun Dang Pharm. Co., Ltd	84.83 Billion KRW	10.896%
Hyundai Bioscience Co., Ltd.	14.82 Billion KRW	-409.858%
ABL Bio Inc.	65.52 Billion KRW	-15.36%
Cellid, Co., Ltd.	10.97 Billion KRW	-588.743%